Latest news with #MET
Business Wire
4 days ago
- Business
- Business Wire
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France--(BUSINESS WIRE)--Regulatory News: We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg ®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg ® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: 'We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg ® (MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy.' Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Yahoo
6 days ago
- Business
- Yahoo
3 Reasons to Sell MET and 1 Stock to Buy Instead
Over the past six months, MetLife's stock price fell to $77.79. Shareholders have lost 10.5% of their capital, which is disappointing considering the S&P 500 has climbed by 5.8%. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation. Is now the time to buy MetLife, or should you be careful about including it in your portfolio? Check out our in-depth research report to see what our analysts have to say, it's free. Why Do We Think MetLife Will Underperform? Even with the cheaper entry price, we're cautious about MetLife. Here are three reasons why you should be careful with MET and a stock we'd rather own. 1. Declining Net Premiums Earned Reflects Weakness Our experience and research show the market cares primarily about an insurer's net premiums earned growth as investment and fee income are considered more susceptible to market volatility and economic cycles. MetLife's net premiums earned has declined by 1.1% annually over the last two years, much worse than the broader insurance industry. This shows that policy underwriting underperformed its other business lines. 2. EPS Barely Growing We track the long-term change in earnings per share (EPS) because it highlights whether a company's growth is profitable. MetLife's EPS grew at a weak 4.4% compounded annual growth rate over the last five years. On the bright side, this performance was better than its 2.2% annualized revenue growth and tells us the company became more profitable on a per-share basis as it expanded. 3. Declining BVPS Reflects Erosion of Asset Value We consider book value per share (BVPS) a critical metric for insurance companies. BVPS represents the total net worth per share, providing insight into a company's financial strength and ability to meet policyholder obligations. Disappointingly for investors, MetLife's BVPS declined at a 1.2% annual clip over the last two years. Final Judgment We see the value of companies helping consumers, but in the case of MetLife, we're out. After the recent drawdown, the stock trades at 2× forward P/B (or $77.79 per share). At this valuation, there's a lot of good news priced in - we think there are better opportunities elsewhere. Let us point you toward an all-weather company that owns household favorite Taco Bell. Stocks We Like More Than MetLife When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
24-07-2025
- Business
- Business Wire
MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux
LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux. Under the liquidity contract entered between MaaT Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30 th, 2025: 35,760 shares €31,444.35 Number of executions on buy side on semester: 3,000 Number of executions on sell side on semester: 2,581 Traded volume on buy side on semester: 85,600 shares for €529,308.98 Traded volume on sell side on semester: 77,516 shares for €494,038.74 As a reminder: the following resources appeared on the last half year statement on 31 December 2024 in the liquidity account: 27,676 shares €66,252.16 Number of executions on buy side on semester: 1,085 Number of executions on sell side on semester: 1,030 Traded volume on buy side on semester: 32,984 shares for €251,038.29 Traded volume on sell side on semester: 32,237 shares for € 249,744.48 the following resources appeared on the liquidity account when the activity started: 0 shares €200,000.00 The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22 nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice. Buy Side Sell Side Number of executions Number of shares Traded volume in EUR Number of executions Number of shares Traded volume in EUR Total 3,000 85,600 529,308.98 2,581 77,516 494,038.74 01/02/2025 17 290 2,317.10 13 377 3,027.31 01/03/2025 2 12 95.76 3 81 648.81 01/06/2025 6 172 1,388.04 18 436 3,535.96 01/07/2025 2 75 608.25 4 92 747.96 01/08/2025 12 267 2,152.02 1 25 202.00 01/09/2025 - - - 74 2,905 26,755.05 01/10/2025 33 1,381 11,586.59 14 562 5,041.14 01/13/2025 28 1,015 8,160.60 29 1,034 8,385.74 01/14/2025 18 465 3,766.50 26 857 7,035.97 01/15/2025 27 1,010 8,170.90 14 506 4,103.66 01/16/2025 14 550 4,411.00 6 189 1,527.12 01/17/2025 9 350 2,810.50 4 94 764.22 01/20/2025 13 363 2,958.45 36 1,040 8,517.60 01/21/2025 19 569 4,739.77 18 505 4,226.85 01/22/2025 12 400 3,316.00 12 360 3,006.00 01/23/2025 23 603 4,938.57 11 465 3,831.60 01/24/2025 26 750 6,045.00 16 253 2,061.95 01/27/2025 20 597 4,805.85 19 451 3,657.61 01/28/2025 17 505 4,055.15 11 420 3,385.20 01/29/2025 28 713 5,732.52 19 525 4,273.50 01/30/2025 31 735 5,902.05 19 695 5,636.45 01/31/2025 62 2,252 17,182.76 58 2,017 15,732.60 02/03/2025 52 1,582 11,865.00 14 428 3,222.84 02/04/2025 19 716 5,291.24 30 850 6,341.00 02/05/2025 2 70 516.60 9 260 1,924.00 02/06/2025 8 270 2,000.70 23 791 5,916.68 02/07/2025 19 540 4,087.80 15 570 4,354.80 02/10/2025 28 845 6,236.10 5 140 1,034.60 02/11/2025 22 340 2,482.00 10 244 1,790.96 02/12/2025 27 780 5,740.80 26 766 5,683.72 02/13/2025 21 423 3,096.36 16 513 3,791.07 02/14/2025 25 812 5,911.36 13 410 3,005.30 02/17/2025 21 663 4,733.82 12 370 2,664.00 02/18/2025 7 140 995.40 21 609 4,360.44 02/19/2025 16 432 3,067.20 7 150 1,065.00 02/20/2025 37 1,280 8,704.00 33 925 6,336.25 02/21/2025 13 525 3,507.00 11 295 1,985.35 02/24/2025 13 334 2,241.14 13 373 2,514.02 02/25/2025 13 368 2,465.60 7 165 1,113.75 02/26/2025 12 284 1,894.28 11 350 2,348.50 02/27/2025 30 983 6,409.16 9 210 1,392.30 02/28/2025 20 547 3,495.33 20 403 2,591.29 03/03/2025 21 654 4,100.58 16 460 2,898.00 03/04/2025 55 1,381 8,493.15 19 371 2,344.72 03/05/2025 12 300 1,815.00 30 977 6,008.55 03/06/2025 30 790 4,850.60 3 130 798.20 03/07/2025 9 255 1,555.50 7 325 1,992.25 03/10/2025 7 250 1,507.50 - - - 03/11/2025 41 1,282 7,486.88 9 317 1,895.66 03/12/2025 55 1,559 9,322.82 75 2,475 15,023.25 03/13/2025 38 843 4,897.83 13 419 2,442.77 03/14/2025 17 505 2,929.00 23 856 5,024.72 03/17/2025 12 405 2,442.15 18 448 2,714.88 03/18/2025 12 296 1,764.16 6 74 445.48 03/19/2025 33 890 5,678.20 76 1,890 12,152.70 03/20/2025 42 1,426 8,670.08 11 269 1,654.35 03/21/2025 33 896 5,205.76 7 255 1,501.95 03/24/2025 9 244 1,390.80 1 40 229.60 03/25/2025 4 95 555.75 31 1,010 5,898.40 03/26/2025 5 195 1,193.40 40 1,364 8,361.32 03/27/2025 35 1,112 7,027.84 40 1,233 8,088.48 03/28/2025 46 1,617 10,041.57 28 1,004 6,365.36 03/31/2025 51 1,393 8,330.14 45 1,686 10,234.02 04/01/2025 11 289 1,849.60 29 825 5,321.25 04/02/2025 30 879 5,493.75 54 1,837 11,958.87 04/03/2025 46 1,140 6,931.20 6 97 612.07 04/04/2025 38 1,365 7,930.65 25 719 4,421.85 04/07/2025 9 350 1,928.50 44 1,323 7,752.78 04/08/2025 13 405 2,579.85 38 1,140 7,330.20 04/09/2025 23 665 4,156.25 6 181 1,138.49 04/10/2025 20 645 3,973.20 19 504 3,190.32 04/11/2025 15 405 2,425.95 8 109 667.08 04/14/2025 10 204 1,207.68 11 345 2,059.65 04/15/2025 8 164 993.84 39 1,090 6,638.10 04/16/2025 32 978 5,926.68 29 1,086 6,689.76 04/17/2025 24 678 4,088.34 3 87 526.35 04/22/2025 15 496 2,921.44 6 195 1,152.45 04/23/2025 13 350 2,086.00 19 525 3,150.00 04/24/2025 14 446 2,604.64 6 213 1,250.31 04/25/2025 21 404 2,391.68 27 813 4,845.48 04/28/2025 36 833 4,923.03 26 750 4,492.50 04/29/2025 35 789 4,639.32 24 660 3,946.80 04/30/2025 33 898 5,217.38 19 501 2,970.93 05/02/2025 14 321 1,848.96 18 330 1,920.60 05/05/2025 35 1,074 6,143.28 11 245 1,408.75 05/06/2025 31 930 5,170.80 17 414 2,343.24 05/07/2025 13 446 2,435.16 12 400 2,204.00 05/08/2025 14 435 2,388.15 25 785 4,341.05 05/09/2025 18 610 3,367.20 11 253 1,419.33 05/12/2025 76 2,743 14,428.18 61 1,840 9,880.80 05/13/2025 49 1,329 6,897.51 34 1,026 5,417.28 05/14/2025 65 1,991 10,193.92 49 1,689 8,765.91 05/15/2025 17 474 2,407.92 15 365 1,868.80 05/16/2025 24 606 3,048.18 16 532 2,697.24 05/19/2025 31 684 3,392.64 20 563 2,809.37 05/20/2025 21 485 2,444.40 16 486 2,468.88 05/21/2025 13 431 2,146.38 24 551 2,766.02 05/22/2025 18 395 1,978.95 22 590 2,997.20 05/23/2025 56 1,383 6,859.68 37 961 4,805.00 05/26/2025 23 713 3,401.01 15 457 2,239.30 05/27/2025 32 885 4,363.05 31 884 4,420.00 05/28/2025 13 260 1,271.40 11 193 951.49 05/29/2025 12 328 1,613.76 17 544 2,692.80 05/30/2025 6 165 816.75 30 758 3,797.58 06/02/2025 25 753 3,697.23 10 255 1,318.35 06/03/2025 28 760 3,883.60 68 2,323 12,846.19 06/04/2025 103 2,830 15,366.90 16 407 2,271.06 06/05/2025 26 748 4,046.68 41 1,109 6,099.50 06/06/2025 39 1,057 5,707.80 25 771 4,217.37 06/09/2025 33 850 4,615.50 20 683 3,756.50 06/10/2025 32 954 4,998.96 15 390 2,059.20 06/11/2025 6 149 785.23 27 750 4,012.50 06/12/2025 20 434 2,308.88 14 409 2,224.96 06/13/2025 34 841 4,507.76 26 825 4,496.25 06/16/2025 18 611 3,274.96 21 697 3,742.89 06/17/2025 18 395 2,069.80 11 318 1,675.86 06/18/2025 27 467 2,447.08 13 304 1,611.20 06/19/2025 32 602 3,166.52 21 516 2,750.28 06/20/2025 23 500 2,635.00 11 320 1,699.20 06/23/2025 18 536 2,749.68 12 272 1,411.68 06/24/2025 27 606 3,072.42 14 404 2,072.52 06/25/2025 27 660 3,267.00 16 427 2,147.81 06/26/2025 11 203 1,012.97 14 335 1,681.70 06/27/2025 28 682 3,314.52 9 250 1,252.50 06/30/2025 7 495 2,351.25 19 571 2,746.51 Expand About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Malaysian Reserve
18-07-2025
- Business
- Malaysian Reserve
GroundWork Appoints Jim Crimmins as Chief Technology Officer
Jim will unify and elevate technology across solar intelligence platform. MONTEREY, Calif., July 17, 2025 /PRNewswire/ — GroundWork Renewables, the full-stack provider of trusted solar data for performance optimization, is pleased to announce the promotion of Jim Crimmins to Chief Technology Officer (CTO). Jim, formerly Executive Vice President at GroundWork, also leads the photovoltaic (PV) Test Lab in Albuquerque, NM—a premier PV module and system performance testing facility acquired by GroundWork in September 2024. With deep experience in PV technology, module testing, and performance analytics, Jim brings the expertise needed to unify GroundWork's data, lab and field services under a cohesive technology strategy. As CTO, he will ensure our tools and data work seamlessly together to support developers, EPCs, module manufacturers and asset owners with precision and clarity. 'Jim has long been at the forefront of PV performance testing, and his ability to identify what truly impacts utility-scale solar performance is unparalleled,' said Ann Will, CEO of GroundWork Renewables. 'As CTO, he will ensure that GroundWork stays ahead of the curve — delivering precision insights, tools, and accuracy our clients and the industry increasingly demand.' Under Jim's leadership at the former CFV Labs, the organization established itself as a trusted partner to developers, EPCs, asset owners, and module manufacturers seeking objective, data-driven evaluation of PV modules and systems. His appointment to CTO reflects the company's commitment to being the industry's performance partner across the entire life cycle of utility-scale solar. 'I'm excited to take on the role of CTO at such a pivotal time for the solar industry,' said Jim Crimmins. 'GroundWork is equipped to transform how the industry understands and optimizes utility-scale solar performance. By combining rigorous field and lab data with technical insight, we have the opportunity to elevate decision-making from development through operations. My goal is to ensure our clients get actionable, high-fidelity intelligence that drives performance, de-risks investment, and ultimately accelerates the energy transition.' The appointment comes as GroundWork scales operations in response to the maturing solar industry and increasing demand for bankable solar data and performance diagnostics. Jim's leadership will propel GroundWork's ability to serve more clients with greater technical depth, while reinforcing its reputation for rigor, quality, and impact. About GroundWork RenewablesGroundWork Renewables is the solar industry's trusted full-stack performance partner. We are the leading provider of high-quality meteorological (MET) data and ISO-accredited PV lab testing, empowering solar plant owners with complete situational awareness of both planned and operating assets. Our solar intelligence reduces uncertainty, enhances modeling and forecasting, and mitigates risk to maximize value across every phase of the plant lifecycle. A certified B Corp, GroundWork is committed to innovation, sustainability, and supporting the global transition to renewable energy. Media Contact: GroundWork Renewables, Loziermarketing@
Yahoo
14-07-2025
- Business
- Yahoo
MetLife's Quarterly Earnings Preview: What You Need to Know
New York-based MetLife, Inc. (MET) is a financial services company that provides insurance, annuities, employee benefits, and asset management services worldwide. With a market cap of $52.2 billion, the company operates in six segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. MET is poised to report its fiscal 2025 Q2 earnings on Wednesday, August 6, after the market closes. Ahead of this event, analysts expect the company to report a profit of $2.21 per share, down 3.1% from $2.28 per share in the year-ago quarter. The company has surpassed the Street's bottom-line projections in one of the past four quarters, while missing on three other occasions. Shopify Stock is a Bargain - How to Make a 3.2% One-Month Yield with SHOP Tariffs, Inflation and Other Key Things to Watch this Week Stocks Set to Open Lower as Trump Ratchets Up Tariff Threats, U.S. Inflation Data and Big Bank Earnings Awaited Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For fiscal 2025, analysts expect MET to report a profit of $8.96, up 10.5% from $8.11 in fiscal 2024. Furthermore, its EPS is expected to grow 14.3% year over year to $10.24 in fiscal 2026. MET stock has grown 7.3% over the past 52 weeks, underperforming the Financial Select Sector SPDR Fund's (XLF) 23.5% surge and the S&P 500 Index's ($SPX) 12.1% uptick during the same time frame. MET stock declined 1.4% following the release of its Q1 results on Apr. 30. The company's overall adjusted revenues for the quarter increased 10.6% year over year to $18.8 billion, beating the Street's expectations. Its adjusted EPS for the quarter rose 7.1% from the prior year's quarter to $1.96, but failed to touch the consensus estimates by 1.5%. Wall Street analysts are highly bullish about MET's stock, with a "Strong Buy" rating overall. Among 17 analysts covering the stock, 12 recommend "Strong Buy," one suggests a 'Moderate Buy,' and four recommend a 'Hold.' MET's average analyst price target of $95.73 indicates a potential upside of 23.2% from the current levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
